Pages
Products

miR-hsa-miR-206 mimics

For research use only. Not intended for any clinical use.

Cat. No. :   MIMH0938

Inquire for Price

Product Information

Cat. No. MIMH0938
Species Human
Size 5 nmol
Sequence UGGAAUGUAAGGAAGUGUGUGG
Inventory 5-7 days
Quick Inquiry

Case Study

Q & A

Customer Reviews

Case Study 1

cMet and Cdk6 mediated the inhibitory effect of miR-206 on the development of HCC in both AKT/Ras and cMyc mice. cMet and Cdk6 mediated the inhibitory effect of miR-206 on the development of HCC in both AKT/Ras and cMyc mice.

MicroRNA‐206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met proto‐oncogene and cyclin‐dependent kinase 6 in mice

Paper 2017
Hepatology | DOI
Background
Hepatocellular carcinoma (HCC) remains lethal with few therapies. This study shows microRNA-206 is downregulated in mouse and human HCC. MiR-206 directly targets cMET, CCND1, and CDK6, delaying cell-cycle progression, reducing proliferation, and inducing apoptosis in HCC cell lines. Systemic miR-206 delivery completely prevented HCC in cMyc and AKT/Ras mice, while cMet or Cdk6 restoration rescued tumor growth. MiR-206 also showed therapeutic efficacy in cMyc and xenograft models. These findings identify miR-206 as a potent tumor suppressor and promising therapeutic strategy for HCC.
Key Findings
MiR-206 was consistently underexpressed in livers of AKT/Ras and cMyc HCC mice, human HCC tumors, and HCC cell lines. Bioinformatic and molecular analyses identified cMET, CCND1, and CDK6 as direct miR-206 targets; miR-206 reduced their mRNA and protein levels and inhibited luciferase reporters containing their wild-type 3′UTRs. In Huh7, SNU449, and MHCC97-H cells, stable miR-206 expression impaired colony formation and proliferation, delayed G1/S progression, and induced apoptosis; target protectors against cMET, CDK6, or CCND1 reversed these effects. In vivo, miR-206 delivery fully prevented HCC in both cMyc and AKT/Ras mice, whereas control mice died from tumor burden. Reintroduction of cMet or Cdk6, but not Ccnd1, restored HCC growth, establishing cMet and Cdk6 as key mediators. MiR-206 also inhibited xenograft tumor growth and showed therapeutic activity in cMyc mice.
Contribution
Creative Biogene provided the chemically modified miR-206 mimic and scramble control used for in vitro and in vivo experiments. The mimic had phosphorothioate and 2′-methoxy modifications, enabling efficient delivery and stable miR-206 overexpression, which was essential for demonstrating miR-206’s tumor-suppressive and therapeutic effects in HCC models.

Case Study 2

Effect of miR-206 overexpression on HCC cell viability Effect of miR-206 overexpression on HCC cell viability

MiRNA-206 inhibits hepatocellular carcinoma cell proliferation and migration but promotes apoptosis by modulating cMET expression

Paper 2019
Acta Biochimica et Biophysica Sinica | DOI
Background
This study investigates microRNA-206 (miR-206) in hepatocellular carcinoma (HCC). miR-206 was downregulated in human HCC tissues, mouse HCC tumors, and HCC cell lines, while cMET was upregulated and inversely correlated. Overexpression of miR-206 reduced HCC cell viability, colony formation, migration, and invasion, and increased apoptosis. Luciferase assays identified cMET as a direct miR-206 target via its 3′-UTR. Restoring cMET reversed miR-206-mediated inhibition, and miR-206 suppressed xenograft tumor growth in mice. The findings suggest miR-206 acts as a tumor suppressor in HCC by targeting cMET.
Key Findings
miR-206 expression was significantly reduced in 27 human HCC tissues, a mouse HCC model, and HepG2, SMMC-7721, and Huh7 cells compared with normal liver. Conversely, cMET was upregulated and negatively correlated with miR-206. miR-206 overexpression inhibited cell viability, DNA synthesis, colony formation, migration, and invasion, and promoted apoptosis, with increased caspase-3/7 activity and Bax, decreased Bcl-2. Dual-luciferase reporter assays confirmed direct binding to the cMET 3′-UTR, reducing cMET mRNA and protein. Restoring cMET reversed miR-206-induced inhibition of growth, migration, and apoptosis. In vivo, miR-206-expressing HepG2 xenografts grew more slowly and weighed less than controls, supporting miR-206 as a tumor suppressor targeting cMET in HCC.
Contribution
Creative Biogene provided the miR-206 mimic, negative control mimic, miR-206 antisense oligonucleotide (ASO), and negative control ASO used for all transfections. These reagents enabled the gain- and loss-of-function experiments that established miR-206-mediated inhibition of HCC proliferation, migration, invasion, apoptosis, and cMET targeting.
Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction